Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Wright Medical Group Inc Raises Low End Of Prior FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Reaffirms FY 2013 EPS Guidance; Comments On FY 2013 Charge Guidance


Monday, 4 Nov 2013 04:00pm EST 

Wright Medical Group Inc announced that for fiscal 2013, the Company is narrowing its previous guidance range of $235 million to $240 million and now anticipates net sales from continuing operations, or Extremity and Biologics revenue, of approximately $237 million to $240 million, which anticipates some potential minor, short-term dis-synergies due to the previously announced transaction with MicroPort. The Company continues to anticipate adjusted earnings per share from continuing operations, including stock-based compensation, to be in the range of $(0.55) to $(0.59) per diluted share. While the amount of the non-cash stock-based compensation charges will vary depending upon a number of factors, the Company currently estimates that the after-tax impact of those expenses will be approximately $0.14 per diluted share for fiscal 2013. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $238 million and EPS of $(0.55) for fiscal 2013. 

Company Quote

31.86
0.37 +1.17%
24 Oct 2014